Skip to content

Ligand Pharmaceuticals LGND Intangible assets — net

Intangible assets — net at other companies

Revvity logo
RevvityRVTY
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Kiniksa Pharmaceuticals International, plc logo
Kiniksa Pharmaceuticals International, plcKNSA
AbbVie logo
AbbVieABBV
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ

Other financials

Income statement

See full
Revenue$51.7M+14.1%
Operating income$17.4M+148%
Net income-$13.3M+68.6%
EPS (diluted)-$0.67+69.7%

Balance sheet

See full
Cash & equivalents$115.1M+140%
Total debt$5.1M+14.2%
Total equity$997.3M+25.4%
Total assets$1.5B+69.2%

Cash flow

See full
Operating cash flow$48.7M+291%
CapEx$228.0K+6.5%
Free cash flow$48.5M+289%

Valuation

See full
Market cap$5.6B+96.7%

Profitability

See full
Gross margin91.9%
Operating margin34.5%+23.0pp
Net margin55.9%+35.7pp
FCF margin44.8%+16.8pp

Returns & leverage

See full
Return on equity17.1%+11.5pp
Debt / equity0.0×
Current ratio21.3×+16.0×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsNet.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ligand Pharmaceuticals's intangible assets — net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ligand Pharmaceuticals's intangible assets — net?
Ligand Pharmaceuticals (LGND) reported intangible assets — net of $217.34M in Q1 2026.
How has Ligand Pharmaceuticals's intangible assets — net changed year-over-year?
Ligand Pharmaceuticals's intangible assets — net decreased by 15.9% year-over-year, from $258.39M to $217.34M.